Qun Chen
Hao Yuan
Peng-Fei Wu- 1Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- 2Pancreas Institute, Nanjing Medical University, Nanjing, China
Editorial on the Research Topic
m6A methylation and cancer immunity
N6-methyladenosine (m6A) is the most prevalent and well-characterized internal RNA modification in eukaryotic cells. Acting at the post-transcriptional level, it regulates RNA splicing, export, stability, and translation, thereby maintaining cellular homeostasis and coordinating stress responses (1, 2). The deposition and removal of m6A are controlled by three classes of enzymes including writers such as METTL3, METTL14, and WTAP, erasers such as FTO and ALKBH5, and readers such as YTHDFs and IGF2BPs, whose coordinated activity ensures precise regulation of RNA metabolism (3–5). Recent evidence indicates that m6A functions not only as a key epitranscriptomic mechanism for cell differentiation and metabolic regulation but also as a central regulator of tumor immunity (6). By modulating antigen presentation, interferon signaling, and immune cell differentiation, m6A shapes the tumor immune microenvironment (TIME) and determines immune evasion and responsiveness to immunotherapy (7, 8). In innate immunity, m6A prevents the accumulation of endogenous double-stranded RNA, limiting aberrant interferon activation and maintaining immune balance, while in adaptive immunity it regulates the differentiation and effector functions of CD8+ T cells, dendritic cells, and tumor-associated macrophages, thereby influencing the formation of an immunosuppressive microenvironment and altering therapeutic sensitivity (9, 10). Pharmacological inhibition of m6A methyltransferases induces double-stranded RNA accumulation and activates interferon signaling, which enhances antigen presentation and improves the efficacy of PD-1 blockade therapy (11). Overall, m6A methylation represents a convergence point linking metabolic reprogramming, epitranscriptomic regulation, and immune microenvironment remodeling, serving as an essential integrator of tumor-immune interactions. In this context, Frontiers in Immunology introduces the Research Topic “m6A Methylation and Cancer Immunity”, which highlights recent advances in m6A-mediated immune regulation and explores its mechanistic and translational implications for immune evasion, therapeutic response, and combination strategies. The following articles illustrate the latest progress in this rapidly evolving field.
Li et al. reviewed recent advances in m6A modification in hepatocellular carcinoma (HCC) immunotherapy, emphasizing its molecular mechanisms in immune evasion and therapeutic response. The review shows that m6A modification regulates essential immune processes such as antigen presentation, immune checkpoint activity, and remodeling of the TIME, thereby influencing tumor immune dynamics. Evidence indicates that METTL3, METTL14, and YTHDF1 facilitate immune evasion by increasing the expression of immunosuppressive molecules and impairing effector T-cell function, while aberrant activation of FTO and ALKBH5 reorganizes cytokine networks and promotes immune tolerance. The authors also highlight the potential synergy between m6A regulation and immune checkpoint blockade therapy and propose that targeting m6A-modifying enzymes could enhance immunotherapeutic efficacy. Overall, the review identifies m6A modification as a key regulator of immune responses in HCC and offers valuable insight into tumor immune dysregulation and strategies for precision immunotherapy.
Liu et al. reviewed the regulatory network and translational potential of m6A modification in HCC immunotherapy, offering new insights into its role in shaping the TIME. The review indicates that m6A promotes immune evasion through modulation of the PD-1/PD-L1 pathway and is associated with myeloid-derived suppressor cell recruitment, reduced antigen presentation by dendritic cells, and T-cell exhaustion. m6A modification also interacts with tumor metabolic reprogramming and cellular stress pathways, together influencing immune persistence and therapeutic responsiveness. The authors emphasize that m6A represents a promising biomarker for predicting immunotherapy outcomes, as its molecular signatures may guide patient stratification and response evaluation. Furthermore, targeting key m6A regulators could reprogram the immunosuppressive milieu, enhance immune cell cytotoxicity, and overcome treatment resistance. Overall, this review deepens current understanding of m6A-mediated immune regulation in HCC and provides a conceptual framework for developing RNA modification-based immunotherapeutic strategies.
Zhou et al. developed an integrated model combining DNA methylation markers of circulating tumor cells (CTCs) with immune infiltration features to assess recurrence and prognosis in stage III-IV colorectal cancer (CRC). Using matched plasma and tissue samples, the study identified 603 overlapping methylation sites and pinpointed ZNF671 and ZNF132 as key biomarkers. A risk model based on these genes accurately predicted recurrence in stage III patients (AUC = 0.90) and negatively correlated with the Immunoscore, indicating that higher methylation levels were linked to reduced immune infiltration and poorer prognosis. Subsequent analyses showed that ZNF671 and ZNF132 methylation was strongly associated with immune cell infiltration, cytokine signaling, and immune checkpoint gene expression, particularly PD-1, PD-L1, and CTLA-4. This study is the first to integrate ctDNA methylation profiling with TIME characteristics, offering a novel biomarker-based approach for early recurrence prediction and personalized immunotherapy in CRC.
Liu and Kan reviewed recent progress in developing small-molecule and peptide inhibitors that target m6A regulators and examined their potential roles in cancer immune regulation and therapy. The review notes that m6A-related writers, erasers, and readers have become attractive therapeutic targets, and inhibitors against METTL3, FTO, ALKBH5, IGF2BP, and YTH domain family proteins are being actively investigated. Modulating m6A levels through these inhibitors affects immune checkpoint expression, antigen presentation, and immune cell function, thereby reshaping the TIME and improving responses to immunotherapy. The authors point out that m6A-targeted therapeutics show strong potential for combination strategies with immune checkpoint blockade, radiotherapy, and metabolic interventions, although issues such as target specificity, pharmacokinetic properties, and safety profiles still need to be addressed. Overall, this review advances understanding of how m6A regulation intersects with cancer immunity and provides valuable direction for developing RNA modification-based targeted therapies.
In summary, this Research Topic provides a comprehensive overview of recent advances in m6A-mediated immune regulation, spanning from fundamental mechanisms to clinical translation. It highlights the pivotal role of m6A in immune evasion, immunotherapy response, and therapeutic innovation. Collectively, these studies deepen our understanding of m6A-immune interactions and offer valuable perspectives for developing RNA modification-based precision immunotherapy strategies.
Author contributions
QC: Writing – original draft. HY: Writing – review & editing. P-FW: Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article.This study was supported by the National Natural Science Foundation of China (No. 82503791).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Li Y, Jin H, Li Q, Shi L, Mao Y, and Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. (2024) 23:130. doi: 10.1186/s12943-024-02041-8
2. Amir M, Khan ZA, Asad A, and Shaikh TG. Role of neoadjuvant pembrolizumab in advanced melanoma. Semin Oncol. (2024) 51:161–2. doi: 10.1053/j.seminoncol.2024.09.001
3. Kim GW, Imam H, Khan M, Mir SA, Kim SJ, Yoon SK, et al. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC. Hepatol (Baltimore Md.). (2021) 73:533–47. doi: 10.1002/hep.31313\
4. Wang J, Fan P, Shen P, Fan C, Zhao P, Yao S, et al. XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer. Cancer Lett. (2024) 596:216846. doi: 10.1016/j.canlet.2024.216846
5. Badraldin SQ, Alfarttoosi KH, Sameer HN, Bishoyi AK, Ganesan S, Shankhyan A, et al. Mechanistic role of FTO in cancer pathogenesis, immune evasion, chemotherapy resistance, and immunotherapy response. Semin Oncol. (2025) 52:152368. doi: 10.1016/j.seminoncol.2025.152368
6. Gao Y, Vasic R, Song Y, Teng R, Liu C, Gbyli R, et al. m(6)A modification prevents formation of endogenous double-stranded RNAs and deleterious innate immune responses during hematopoietic development. Immunity. (2020) 52:1007–1021.e8. doi: 10.1016/j.immuni.2020.05.003
7. Wang T, Han L, Huo Y, Zhang L, Huang Y, Zhang N, et al. H3K36me3-guided m(6)A modification of oncogenic L1CAM-AS1 drives macrophage polarization and immunotherapy resistance in hepatocellular carcinoma. Adv Sci (Weinh). (2025) 12:e14909. doi: 10.1002/advs.202414909
8. Zhang H, Luo X, Yang W, Wu Z, Zhao Z, Pei X, et al. YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity. Nat Commun. (2024) 15:9559. doi: 10.1038/s41467-024-53997-6
9. Bao Y, Zhai J, Chen H, Wong CC, Liang C, Ding Y, et al. Targeting m(6)A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut. (2023) 72:1497–509. doi: 10.1136/gutjnl-2022-328845
10. Mak TK, Li K, Zhao Z, Wang K, Zeng L, He Q, et al. m6A demethylation of NNMT in CAFs promotes gastric cancer progression by enhancing macrophage M2 polarization. Cancer Lett. (2024) 611:217422. doi: 10.1016/j.canlet.2024.217422
Keywords: M6A, cancer, immune, RNA modification, precise treatment
Citation: Chen Q, Yuan H and Wu P-F (2025) Editorial: m6A methylation and cancer immunity. Front. Immunol. 16:1726760. doi: 10.3389/fimmu.2025.1726760
Received: 16 October 2025; Accepted: 21 October 2025;
Published: 28 October 2025.
Edited and reviewed by:
Vassiliki A Boussiotis, Beth Israel Deaconess Medical Center and Harvard Medical School, United StatesCopyright © 2025 Chen, Yuan and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hao Yuan, eXVhbmhhb0Buam11LmVkdS5jbg==; Peng-Fei Wu, d3VwZW5nZmVpQG5qbXUuZWR1LmNu
†These authors have contributed equally to this work